Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
61-80 of 2,120 trials

Merkel Cell Carcinoma: Pembrolizumab with Chemotherapy

We are studying a new treatment combining pembrolizumab with chemotherapy for patients with advanced Merkel cell carcinoma. The goal is to see if this combination is effective and safe for those who haven't been treated before.

Merkel Cell CarcinomaEfficacy phase (II)No PlaceboStandard MedicinesDermatologyOncology

Cirrhosis and Ascites: Personalized Human Albumin Treatment

We are studying a tailored approach to human albumin therapy for patients with liver cirrhosis and fluid buildup. The goal is to identify who may respond best to this treatment.

Liver Cirrhosis>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesCost ReimbursementHepatologyInternal Medicine

Early Breast Cancer: Imlunestrant vs Standard Therapy

We are studying a new treatment called imlunestrant for patients with early breast cancer who have already received 2 to 5 years of standard therapy. The goal is to see if it helps reduce the risk of cancer returning compared to current treatments.

Breast Cancer>2 yearsConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Early Breast Cancer: Camizestrant vs. Standard Therapy

We are studying whether the new medication camizestrant can better prevent breast cancer recurrence in patients who have completed initial treatment. This trial involves individuals with ER+/HER2- early breast cancer at risk of returning after standard therapy.

ER+/HER2- Early Breast Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Multiple Sclerosis: Rituximab vs. Ocrelizumab Study

We are comparing two treatments for relapsing-remitting multiple sclerosis to see if rituximab is as effective as ocrelizumab in preventing disease activity. This study also examines patient quality of life and other important factors.

Multiple Sclerosis1-2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsStandard MedicinesNeurology

Acute Lymphoblastic Leukaemia: ALLTogether Treatment Study

We are studying new treatment options for children and young adults aged 0-45 with newly diagnosed acute lymphoblastic leukaemia. The goal is to improve survival and quality of life through various interventions.

Acute Lymphoblastic Leukaemia>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

ANCA-Associated Vasculitis: Pioglitazone Treatment

We are studying whether adding pioglitazone to standard treatments can improve kidney function in patients with ANCA-associated vasculitis. The trial also looks at quality of life and potential side effects.

ANCA-associated Vasculitis>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesPartially RemoteNephrologyRheumatology

Semaglutide for Acute Ischemic Stroke

We are studying whether a new injection of semaglutide is safe and effective for non-diabetic patients right after an ischemic stroke. This trial aims to improve treatment options during this critical time.

Ischemic Stroke≤3 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesCardiologyNeurology

Fanconi Anemia: Long-Term Study of RP-L102 Infusion

We are evaluating the long-term safety and health effects of a gene therapy infusion for patients with Fanconi Anemia. This study looks at blood health and potential risks over time.

Fanconi's AnemiaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost Reimbursement

Infantile-onset Pompe Disease: Cipaglucosidase Alfa/Miglustat Study

We are evaluating a new treatment for children under 18 with infantile-onset Pompe disease to see if it is safe and effective. This study includes both children who have and have not received previous enzyme replacement therapy.

Pompe's Disease (Infantile Onset)>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal MedicineNeurologyPediatrics

Understanding Pain in Parkinson's Disease: PET Imaging Study

We are exploring how the serotonin system affects pain in people with Parkinson's disease. This study compares those with and without pain to learn more about their experiences and brain activity.

Parkinson's Disease>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurology

Arthritis from Cancer Immunotherapy: Tocilizumab Study

We are investigating whether adding tocilizumab to short-term glucocorticoids helps people with arthritis caused by cancer immunotherapy more than glucocorticoids alone. This study aims to improve arthritis control and patient outcomes.

Arthritis from Cancer TreatmentEfficacy phase (II)No PlaceboStandard MedicinesOncologyRheumatology

HER2-Positive Early Breast Cancer: Inavolisib Study

We are investigating whether adding the drug inavolisib to standard treatments helps patients with HER2-positive, HR-positive, PIK3CA mutant early breast cancer achieve better treatment responses. This study compares the new combination therapy to standard therapy alone.

Breast Cancer3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Sedation in Older Critically Ill Patients: Dexmedetomidine vs. Placebo

We are studying whether early sedation with dexmedetomidine improves survival and health outcomes in patients aged 65 and older on ventilators. This trial aims to build on previous findings about sedation in critically ill patients.

Critically Ill PatientsMonitoring phase (IV)Standard MedicinesInternal MedicineOtolaryngologyPsychiatryPulmonology

Pancreatic Cancer: mFOLFIRINOX with Radiation Therapy

We are studying whether adding high-dose radiation therapy to standard chemotherapy helps patients with borderline resectable pancreatic cancer have better surgical outcomes and survival rates.

Pancreatic Cancer3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyOncology

Diffuse Large B-Cell Lymphoma: Acalabrutinib with R-miniCHOP

We are studying whether adding acalabrutinib to a reduced chemotherapy regimen helps older adults with untreated diffuse large B-cell lymphoma live longer and have better treatment responses. This trial is for those over 60 or 80 years who cannot receive full-dose chemotherapy.

High-Grade B-Cell Lymphoma>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Ovarian Cancer Treatment: Carboplatin and Mirvetuximab Soravtansine

We are studying a combination of carboplatin and a new drug, Mirvetuximab soravtansine, for patients with recurrent ovarian cancer that is sensitive to platinum-based chemotherapy. This trial aims to see if this treatment improves response rates in patients with specific tumor characteristics.

Ovarian and Fallopian Tube Cancer>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Advanced Solid Tumors: REGN7075 with Cemiplimab

We are studying the safety and effectiveness of a new treatment combining REGN7075 and cemiplimab for patients with advanced cancers. This trial aims to explore how well this combination works and its impact on patients' quality of life.

Malignant Solid TumorSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Cancer Treatment: Long-term Study of Pembrolizumab

We are evaluating the long-term safety and survival of patients currently on pembrolizumab treatment. This study aims to understand how well the treatment works and its effects over time.

Advanced Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Pembrolizumab for Children with Advanced Melanoma and Solid Tumors

We are studying the safety and effectiveness of pembrolizumab in children with advanced melanoma or certain relapsed solid tumors and lymphoma. This trial aims to understand how well this treatment works and its potential side effects.

Advanced Melanoma and Related CancersSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncologyPediatrics